Larvol Delta - BioTheryX-Doses-First-Patient-in-Phase-1-Study-Investigating-Lead-Protein-Degrader-Candidate-BTX1188

BTX-1188 - BioTheryX

https://www.prnewswire.com/news-releases/biotheryx-doses-first-patient-in-phase-1-study-investigating-lead-protein-degrader-candidate-btx-1188-301468224.html

Jan 26, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next